Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

Phase 2

Completed

• Conditions: Alzheimer's Disease

• Registration Number: NCT00074529
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-10
• Study First Submitted: 2003-12-15
• Study First Submitted QC: 2003-12-15
• Study First Posted: 2003-12-16
• Primary Completion: 2006-01
• Study Completion: 2006-01
• Status Verified: 2015-07
• Last Update Submitted: 2015-07-23
• Last Update Posted: 2015-07-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 512

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive function over 12 month period; safety and tolerability	over 12 month period

Secondary Outcome Measures

Name	Time	Method
AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog.	over a 6 month and 12 month period